Skip to main content
Top

01-12-2012 | Research Paper

hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases

Published in: Clinical & Experimental Metastasis | Issue 8/2012

Login to get access

Abstract

We investigated the methylation status of mismatch repair gene hMLH1 in 80 primary human endometrial carcinomas (ECs) and in 30 metastatic lesions. It was correlated to the expression of hMLH1 protein, microsatellite instability (MSI) of ECs and to the well-known clinico-pathological variables of cancer. The hMLH1 promoter methylation was detected in 24 out of 64 (37.5 %) primary ECs but only in one out of 18 (5.6 %) metastatic lesions investigated. Promoter hMLH1 hypermethylation was found more often in early stage ECs and was associated with a decrease of hMLH1 protein expression immunohistochemically. An inverse relationship between hMLH1 expression and clinical stage of the disease was found (p = 0.048). Interestingly, there was a significant correlation between MSI and hMLH1 protein expression level (p = 0.042). MSI phenotype was found more often in EC metastases compared to the primary tumors (66.7 % vs 29.3 %; p = 0.039). However, neither hMLH1 promoter hypermethylation nor MSI was independent predictive factors for patient’s outcome. Using an in vitro model we showed that hMLH1 methylation is reversible. These data showed that hMLH1 methylation with a consequent protein decrease occurred early during EC tumorigenesis and may cause a MSI phenotype, which occurs relatively late. MSI may be an important mechanism supporting further the tumor progression. These findings may have importance for the specific chemosensitization of the primary tumors/metastases and can improve our understanding of endometrial carcinogenesis in humans.
Appendix
Available only for authorised users
Literature
2.
go back to reference Amant F, Moerman P, Neven P, Timmerman D, van Limbergen E, Vegote I (2005) Endometrial cancer. Lancet 366:491–505PubMedCrossRef Amant F, Moerman P, Neven P, Timmerman D, van Limbergen E, Vegote I (2005) Endometrial cancer. Lancet 366:491–505PubMedCrossRef
4.
5.
go back to reference Deligdisch L, Kase NG, Bleiweiss IJ (2000) Endometrial cancer in elderly women: a histologic and steroid receptor study. Gerontology 46:17–21PubMedCrossRef Deligdisch L, Kase NG, Bleiweiss IJ (2000) Endometrial cancer in elderly women: a histologic and steroid receptor study. Gerontology 46:17–21PubMedCrossRef
6.
go back to reference Lax SF (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444:213–223PubMedCrossRef Lax SF (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444:213–223PubMedCrossRef
7.
go back to reference Esteller M (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21:5427–5440PubMedCrossRef Esteller M (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21:5427–5440PubMedCrossRef
8.
go back to reference Esteller M (2000) Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 36:2294–2300PubMedCrossRef Esteller M (2000) Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 36:2294–2300PubMedCrossRef
9.
go back to reference Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Eng J Med 349:2042–2054CrossRef Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Eng J Med 349:2042–2054CrossRef
10.
go back to reference Deng G, Chen A, Hong J, Chae HS, Kim YS (1999) Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 59:2029–2033PubMed Deng G, Chen A, Hong J, Chae HS, Kim YS (1999) Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 59:2029–2033PubMed
12.
go back to reference Clark SJ, Melki J (2002) DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 21:5380–5387PubMedCrossRef Clark SJ, Melki J (2002) DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 21:5380–5387PubMedCrossRef
15.
go back to reference Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG (1998) MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 17:2413–2417PubMedCrossRef Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG (1998) MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 17:2413–2417PubMedCrossRef
16.
go back to reference Esteller M, Catasus L, Matias-Guiu X, Mutter GL, Prat J, Baylin SB, Herman JG (1999) hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 155:1767–1772PubMedCrossRef Esteller M, Catasus L, Matias-Guiu X, Mutter GL, Prat J, Baylin SB, Herman JG (1999) hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 155:1767–1772PubMedCrossRef
17.
go back to reference Kanaya T, Kyo S, Maida Y, Yatabe N, Tanaka M, Nakamura M, Inoue M (2003) Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 22:2352–2360PubMedCrossRef Kanaya T, Kyo S, Maida Y, Yatabe N, Tanaka M, Nakamura M, Inoue M (2003) Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 22:2352–2360PubMedCrossRef
18.
go back to reference Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, Palazzo JP, Fishel R, Goodfellow PJ (1999) MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 8:661–666PubMedCrossRef Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, Palazzo JP, Fishel R, Goodfellow PJ (1999) MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 8:661–666PubMedCrossRef
19.
go back to reference Strazzullo M, Cossu A, Baldinu P, Colombino M, Satta MP, Tanda F, De Bonis ML, Cerase A, D’Urso M, D’Esposito M, Palmieri G (2003) High-resolution methylation analysis of the hMLH1 promoter in sporadic endometrial and colorectal carcinomas. Cancer 98:1540–1546PubMedCrossRef Strazzullo M, Cossu A, Baldinu P, Colombino M, Satta MP, Tanda F, De Bonis ML, Cerase A, D’Urso M, D’Esposito M, Palmieri G (2003) High-resolution methylation analysis of the hMLH1 promoter in sporadic endometrial and colorectal carcinomas. Cancer 98:1540–1546PubMedCrossRef
20.
go back to reference Yang HJ, Liu VW, Wang Y, Tsang PC, Ngan HY (2006) Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6:212PubMedCrossRef Yang HJ, Liu VW, Wang Y, Tsang PC, Ngan HY (2006) Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6:212PubMedCrossRef
21.
go back to reference Zighelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS, Mutch DG (2007) Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol 25:2042–2048PubMedCrossRef Zighelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS, Mutch DG (2007) Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol 25:2042–2048PubMedCrossRef
22.
go back to reference Guida M, Sanguedolce F, Bufo P, Di Spiezio Sardo A, Bifulco G, Nappi C, Pannone G (2009) Aberrant DNA hypermethylation of hMLH-1 and CKDN2A/p16 genes in benign, premalignant and malignant endometrial lesions. Eur J Gynaecol Oncol 30:267–270PubMed Guida M, Sanguedolce F, Bufo P, Di Spiezio Sardo A, Bifulco G, Nappi C, Pannone G (2009) Aberrant DNA hypermethylation of hMLH-1 and CKDN2A/p16 genes in benign, premalignant and malignant endometrial lesions. Eur J Gynaecol Oncol 30:267–270PubMed
23.
go back to reference Muraki Y, Banno K, Yanokura M, Kobayashi Y, Kawaguchi M, Nomura H, Hirasawa A, Susumu N, Aoki D (2009) Epigenetic DNA hypermethylation: clinical applications in endometrial cancer (Review). Oncol Rep 22:967–972PubMed Muraki Y, Banno K, Yanokura M, Kobayashi Y, Kawaguchi M, Nomura H, Hirasawa A, Susumu N, Aoki D (2009) Epigenetic DNA hypermethylation: clinical applications in endometrial cancer (Review). Oncol Rep 22:967–972PubMed
24.
go back to reference Di Domenico M, Santoro A, Ricciardi C, Iaccarino M, Iaccarino S, Freda M, Feola A, Sanguedolce F, Losito S, Pasquali D, Di Spiezio Sardo A, Bifulco G, Nappi C, Bufo P, Guida M, De Rosa G, Abbruzzese A, Caraglia M, Pannone G (2011) Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization. Cancer Biol Ther 12:447–457PubMedCrossRef Di Domenico M, Santoro A, Ricciardi C, Iaccarino M, Iaccarino S, Freda M, Feola A, Sanguedolce F, Losito S, Pasquali D, Di Spiezio Sardo A, Bifulco G, Nappi C, Bufo P, Guida M, De Rosa G, Abbruzzese A, Caraglia M, Pannone G (2011) Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization. Cancer Biol Ther 12:447–457PubMedCrossRef
25.
go back to reference Thomas DC, Umar A, Kunkel TA (1996) Microsatellite instability and mismatch repair defects in cancer. Mutat Res 350:201–205PubMedCrossRef Thomas DC, Umar A, Kunkel TA (1996) Microsatellite instability and mismatch repair defects in cancer. Mutat Res 350:201–205PubMedCrossRef
26.
go back to reference Gurin CC, Federici MG, Kang L, Boyd J (1999) Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 59:462–466PubMed Gurin CC, Federici MG, Kang L, Boyd J (1999) Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 59:462–466PubMed
27.
go back to reference Furlan D, Carnevali I, Marcomini B, Cerutti R, Dainese E, Capella C, Riva C (2006) The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin Cancer Res 12:3329–3336PubMedCrossRef Furlan D, Carnevali I, Marcomini B, Cerutti R, Dainese E, Capella C, Riva C (2006) The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin Cancer Res 12:3329–3336PubMedCrossRef
28.
go back to reference Pijnenborg JM, Dam-de Veen GC, de Haan J, van Engeland M, Groothuis PG (2004) Defective mismatch repair and the development of recurrent endometrial carcinoma. Gynecol Oncol 94:550–559PubMedCrossRef Pijnenborg JM, Dam-de Veen GC, de Haan J, van Engeland M, Groothuis PG (2004) Defective mismatch repair and the development of recurrent endometrial carcinoma. Gynecol Oncol 94:550–559PubMedCrossRef
29.
go back to reference Hirasawa A, Aoki D, Inoue J, Imoto I, Susumu N, Sugano K, Nozawa S, Inazawa J (2003) Unfavorable prognostic factors associated with high frequency of microsatellite instability and comparative genomic hybridization analysis in endometrial cancer. Clin Cancer Res 9:5675–5682PubMed Hirasawa A, Aoki D, Inoue J, Imoto I, Susumu N, Sugano K, Nozawa S, Inazawa J (2003) Unfavorable prognostic factors associated with high frequency of microsatellite instability and comparative genomic hybridization analysis in endometrial cancer. Clin Cancer Res 9:5675–5682PubMed
30.
go back to reference An HJ, Kim KI, Kim JY, Shim JY, Kang H, Kim TH, Kim JK, Jeong JK, Lee SY, Kim SJ (2007) Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol 31:846–853PubMedCrossRef An HJ, Kim KI, Kim JY, Shim JY, Kang H, Kim TH, Kim JK, Jeong JK, Lee SY, Kim SJ (2007) Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol 31:846–853PubMedCrossRef
31.
go back to reference Black D, Soslow RA, Levine DA, Tornos C, Chen SC, Hummer AJ, Bogomolniy F, Olvera N, Barakat RR, Boyd J (2006) Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 24:1745–1753PubMedCrossRef Black D, Soslow RA, Levine DA, Tornos C, Chen SC, Hummer AJ, Bogomolniy F, Olvera N, Barakat RR, Boyd J (2006) Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 24:1745–1753PubMedCrossRef
32.
go back to reference Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD, Frank TS (1996) Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 148:1671–1678PubMed Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD, Frank TS (1996) Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 148:1671–1678PubMed
33.
go back to reference Katabuchi H, van Rees B, Lambers AR, Ronnett BM, Blazes MS, Leach FS, Cho KR, Hedrick L (1995) Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res 55:5556–5560PubMed Katabuchi H, van Rees B, Lambers AR, Ronnett BM, Blazes MS, Leach FS, Cho KR, Hedrick L (1995) Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res 55:5556–5560PubMed
34.
go back to reference Maxwell GL, Risinger JI, Alvarez AA, Barrett JC, Berchuck A (2001) Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 97:417–422PubMedCrossRef Maxwell GL, Risinger JI, Alvarez AA, Barrett JC, Berchuck A (2001) Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 97:417–422PubMedCrossRef
35.
go back to reference Peiro G, Diebold J, Lohse P, Ruebsamen H, Lohse P, Baretton GB, Lohrs U (2002) Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma. Hum Pathol 33:347–354PubMedCrossRef Peiro G, Diebold J, Lohse P, Ruebsamen H, Lohse P, Baretton GB, Lohrs U (2002) Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma. Hum Pathol 33:347–354PubMedCrossRef
36.
go back to reference Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ (1994) Histological typing of female genital tract tumours, 2nd edn. Springer, BerlinCrossRef Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ (1994) Histological typing of female genital tract tumours, 2nd edn. Springer, BerlinCrossRef
37.
go back to reference Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104PubMedCrossRef Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104PubMedCrossRef
38.
go back to reference Semczuk A, Boltze C, Marzec B, Szczygielska A, Roessner A, Schneider-Stock R (2003) p16 INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J Cancer Res Clin Oncol 129:589–596PubMedCrossRef Semczuk A, Boltze C, Marzec B, Szczygielska A, Roessner A, Schneider-Stock R (2003) p16 INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J Cancer Res Clin Oncol 129:589–596PubMedCrossRef
39.
go back to reference Ignatov A, Bischoff J, Ignatov T, Schwarzenau C, Krebs T, Kuester D, Costa SD, Roessner A, Semczuk A, Schneider-Stock R (2010) APC promoter hypermethylation is an early event in endometrial tumorigenesis. Cancer Sci 101:321–327PubMedCrossRef Ignatov A, Bischoff J, Ignatov T, Schwarzenau C, Krebs T, Kuester D, Costa SD, Roessner A, Semczuk A, Schneider-Stock R (2010) APC promoter hypermethylation is an early event in endometrial tumorigenesis. Cancer Sci 101:321–327PubMedCrossRef
40.
go back to reference Ignatov A, Bischoff J, Schwarzenau C, Krebs T, Kuester D, Herrmann K, Costa SD, Roessner A, Semczuk A, Schneider-Stock R (2008) P16 alterations increase the metastatic potential of endometrial carcinoma. Gynecol Oncol 111:365–371PubMedCrossRef Ignatov A, Bischoff J, Schwarzenau C, Krebs T, Kuester D, Herrmann K, Costa SD, Roessner A, Semczuk A, Schneider-Stock R (2008) P16 alterations increase the metastatic potential of endometrial carcinoma. Gynecol Oncol 111:365–371PubMedCrossRef
41.
go back to reference Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248–5257PubMed Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248–5257PubMed
42.
go back to reference Shibata D, Peinado MA, Ionov Y, Malkhosyan S, Perucho M (1994) Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet 6:273–281PubMedCrossRef Shibata D, Peinado MA, Ionov Y, Malkhosyan S, Perucho M (1994) Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet 6:273–281PubMedCrossRef
43.
go back to reference Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T (2010) Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 123:87–96PubMedCrossRef Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T (2010) Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 123:87–96PubMedCrossRef
44.
go back to reference Kondo E, Furukawa T, Yoshinaga K, Kijima H, Semba S, Yatsuoka T, Yokoyama T, Fukushige S, Horii A (2000) Not hMLH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability. Int J Oncol 17:535–541PubMed Kondo E, Furukawa T, Yoshinaga K, Kijima H, Semba S, Yatsuoka T, Yokoyama T, Fukushige S, Horii A (2000) Not hMLH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability. Int J Oncol 17:535–541PubMed
45.
go back to reference Salvesen H, McDonald N, Ryan A, Iversen OE, Jacobs IJ, Akslen LA, Das S (2000) Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 6:3607–3613PubMed Salvesen H, McDonald N, Ryan A, Iversen OE, Jacobs IJ, Akslen LA, Das S (2000) Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 6:3607–3613PubMed
46.
go back to reference Banno K, Yanokura M, Susumu N, Kawaguchi M, Hirao N, Hirasawa A, Tsukazaki K, Aoki D (2006) Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncol Rep 16:1189–1196PubMed Banno K, Yanokura M, Susumu N, Kawaguchi M, Hirao N, Hirasawa A, Tsukazaki K, Aoki D (2006) Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncol Rep 16:1189–1196PubMed
47.
go back to reference Kang S, Kim JW, Kang GH, Lee S, Park NH, Song YS, Park SY, Kang SB, Lee HP (2006) Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int J Cancer 118:2168–2171PubMedCrossRef Kang S, Kim JW, Kang GH, Lee S, Park NH, Song YS, Park SY, Kang SB, Lee HP (2006) Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int J Cancer 118:2168–2171PubMedCrossRef
48.
go back to reference Xiong Y, Dowdy SC, Eberhardt NL, Podratz KC, Jiang SW (2006) hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications. Gynecol Oncol 103:321–328PubMedCrossRef Xiong Y, Dowdy SC, Eberhardt NL, Podratz KC, Jiang SW (2006) hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications. Gynecol Oncol 103:321–328PubMedCrossRef
49.
go back to reference Kim MS, Lee J, Sidransky D (2010) DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 29:181–206PubMedCrossRef Kim MS, Lee J, Sidransky D (2010) DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 29:181–206PubMedCrossRef
50.
go back to reference Kawaguchi M, Banno K, Yanokura M, Kobayashi Y, Kishimi A, Ogawa S, Kisu I, Nomura H, Hirasawa A, Susumu N, Aoki D (2009) Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer. Int J Oncol 35:977–982PubMed Kawaguchi M, Banno K, Yanokura M, Kobayashi Y, Kishimi A, Ogawa S, Kisu I, Nomura H, Hirasawa A, Susumu N, Aoki D (2009) Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer. Int J Oncol 35:977–982PubMed
51.
go back to reference Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95:6870–6875PubMedCrossRef Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95:6870–6875PubMedCrossRef
52.
go back to reference Fleisher AS, Esteller M, Tamura G, Rashid A, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Nishizuka S, James SP, Wilson KT, Herman JG, Meltzer SJ (2001) Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 20:329–335PubMedCrossRef Fleisher AS, Esteller M, Tamura G, Rashid A, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Nishizuka S, James SP, Wilson KT, Herman JG, Meltzer SJ (2001) Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 20:329–335PubMedCrossRef
53.
go back to reference Loeb LA (1994) Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 54:5059–5063PubMed Loeb LA (1994) Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 54:5059–5063PubMed
54.
go back to reference Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC (1999) hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 59:159–164PubMed Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC (1999) hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 59:159–164PubMed
55.
go back to reference Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, Shi YQ, Rhyu MG, Powell SM, James SP, Wilson KT, Herman JG, Meltzer SJ (1999) Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 59:1090–1095PubMed Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, Shi YQ, Rhyu MG, Powell SM, James SP, Wilson KT, Herman JG, Meltzer SJ (1999) Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 59:1090–1095PubMed
56.
go back to reference Fink D, Aebi S, Howell SB (1984) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4:1–6 Fink D, Aebi S, Howell SB (1984) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4:1–6
57.
go back to reference Steele N, Finn P, Brown R, Plumb JA (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 100:758–763PubMedCrossRef Steele N, Finn P, Brown R, Plumb JA (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 100:758–763PubMedCrossRef
58.
go back to reference Jo WS, Carethers JM (2006) Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark 2:51–60PubMed Jo WS, Carethers JM (2006) Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark 2:51–60PubMed
59.
go back to reference Liang J-T, Huang K-C, Lai H-S, Lee P-H, Cheng Y-M, Hsu Y-C, Cheng A-L, Hsu C-H, Yeh K-H, Wang S-M, Tang C, Chang K-J (2002) High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 101:519–525PubMedCrossRef Liang J-T, Huang K-C, Lai H-S, Lee P-H, Cheng Y-M, Hsu Y-C, Cheng A-L, Hsu C-H, Yeh K-H, Wang S-M, Tang C, Chang K-J (2002) High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 101:519–525PubMedCrossRef
60.
go back to reference Magrini R, Bhonde MR, Hanski ML, Notter M, Scherubl H, Boland CR, Zeitz M, Hanski C (2002) Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 101:23–31PubMedCrossRef Magrini R, Bhonde MR, Hanski ML, Notter M, Scherubl H, Boland CR, Zeitz M, Hanski C (2002) Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 101:23–31PubMedCrossRef
61.
go back to reference Fallik D, Borrini F, Boige V, Viguier J, Jacob S, Miquel C, Sabourin JC, Ducreux M, Praz F (2003) Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 63:5738–5744PubMed Fallik D, Borrini F, Boige V, Viguier J, Jacob S, Miquel C, Sabourin JC, Ducreux M, Praz F (2003) Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 63:5738–5744PubMed
62.
go back to reference Basil JB, Goodfellow PJ, Rader JS, Mutch DG, Herzog TJ (2000) Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 89:1758–1764PubMedCrossRef Basil JB, Goodfellow PJ, Rader JS, Mutch DG, Herzog TJ (2000) Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 89:1758–1764PubMedCrossRef
63.
go back to reference Jeczen R, Skomra D, Cybulski M, Schneider-Stock R, Szewczuk W, Roessner A, Rechberger T, Semczuk A (2007) P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome. Clin Exp Metastasis 24:503–511PubMedCrossRef Jeczen R, Skomra D, Cybulski M, Schneider-Stock R, Szewczuk W, Roessner A, Rechberger T, Semczuk A (2007) P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome. Clin Exp Metastasis 24:503–511PubMedCrossRef
64.
go back to reference Szewczuk W, Skomra D, Cybulski M, Prządka-Rabaniuk D, Filip A, Jozwik M, Olcha P, Roessner A, Semczuk A (2009) Allelic loss at TP53 in metastatic human endometrial carcinomas. Clin Exp Metastasis 26:789–796PubMedCrossRef Szewczuk W, Skomra D, Cybulski M, Prządka-Rabaniuk D, Filip A, Jozwik M, Olcha P, Roessner A, Semczuk A (2009) Allelic loss at TP53 in metastatic human endometrial carcinomas. Clin Exp Metastasis 26:789–796PubMedCrossRef
65.
go back to reference Semczuk A, Schneider-Stock R, Szewczuk W (2010) Prevalence of allelic loss at TP53 in endometrial carcinomas. (Review). Oncology 78:220–228PubMedCrossRef Semczuk A, Schneider-Stock R, Szewczuk W (2010) Prevalence of allelic loss at TP53 in endometrial carcinomas. (Review). Oncology 78:220–228PubMedCrossRef
Metadata
Title
hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases
Publication date
01-12-2012
Published in
Clinical & Experimental Metastasis / Issue 8/2012
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-012-9478-0
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine